Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery
NCT ID: NCT04060771
Last Updated: 2019-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
80 participants
INTERVENTIONAL
2018-08-01
2020-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Postoperative Nausea and Vomit in Strabismus Surgery
NCT03806400
Penehyclidine for PONV Prophylaxis After Strabismus Surgery
NCT04054479
Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery
NCT04853147
Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and Vomiting
NCT05439798
Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery
NCT07086118
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: The study aims to compare the incidence of PONV after intravenous administration of palonosetron or dexamethasone in pediatric patients undergoing elective strabismus surgery under general anesthesia.
Materials and Methods: This prospective, double-blind study consist of 80 patients of both genders, classified as ASA grade I and II, ranging in age from 2 to 15 years, scheduled for elective strabismus surgery at Hospital Universitário Antonio Pedro(HUAP), after consent by their parents. Patients will be randomized into two groups of 40 patients each. Group P will receive intravenous dose of palonosetron (1 mg.kg-1), and Group D will receive dexamethasone (0.2 mg.kg-1) after induction of anesthesia. Pacients will be observed for 6 hours before discharge and post-discharge symptoms will be assessed through telephone survey after 24 and 48 hours. At the end of the study, results will be compiled and statistical analysis will be done by using Mann-Whitney test, Chi-squared test and Fisher test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group P
During general anesthesia patients will receive a single intravenous dose of palonosetron 1 mcg.Kg-1.
Palonosetron
prophylaxis of postoperative nausea and vomiting
Group D
During general anesthesia patients will receive a single intravenous dose of dexamethasone 0.2 mg.Kg-1.
Dexamethasone
prophylaxis of postoperative nausea and vomiting
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Palonosetron
prophylaxis of postoperative nausea and vomiting
Dexamethasone
prophylaxis of postoperative nausea and vomiting
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physical state according to an American Society of Anesthesiologists (ASA) I and II
Exclusion Criteria
* Participation in another study in the last month
* Previous history of PONV
* Occurrence of episodes of nausea or vomiting in the last 24 hours before surgery
* Chronic use of corticosteroids
* Previous history of motion sickness
* Use of psychoactive drugs or any other medicine with an antiemetic effect;
* Known hypersensitivity to any study medication
* Severe diseases in organs such as kidney, liver, lung, heart, brain and bone marrow
2 Years
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidade Federal Fluminense
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexandra Rezende Assad, PhD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Júlio CA Moreira, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitário Antonio Pedro
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitário Antonio Pedro
Niterói, Rio de Janeiro, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Strabismus surgery
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.